PubMed
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 63% · Mixed 20% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 400–600 mcg
Reports span 50–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 58% said they felt similar to their last entry, 43% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 17 days · Based on 147 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 52% · Mixed 36% · Unfavorable overall 12%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.1–0.2 mg
Reports span 0.01–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 15 days · Based on 46 repeat reporters
Published sources linked on the BPC-157 Stable and CDP-Choline wiki pages.
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Seiwerth S, Milavic M, Vukojevic J, et al. Frontiers in pharmacology. 2021
PubMed
Sikiric P, Drmic D, Sever M, et al. Current pharmaceutical design. 2020
PubMed
Davalos A, Alvarez-Sabin J, Castillo J, et al. Lancet. 2012
PubMed
Zafonte RD, Bagiella E, Ansel BM, et al. JAMA. 2012
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2006
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2007